The Calmer Co (ASX: CCO) Eyes Global Growth as $25m Distribution Deal and Record Kava Sales Build Momentum

The Calmer Co International (ASX: CCO) is building momentum in the global wellness market after delivering record quarterly revenue of $2.44 million and securing an international distribution agreement carrying approximately $25 million in minimum performance requirements.

Its 12 November 2026 annual general meeting presentation highlights a transformation from a traditional kava producer into a diversified wellness and botanical ingredients business.

With American wholesale demand accelerating, Australian supermarket sales expanding and operating cash outflows declining, the company is establishing a stronger foundation for sustainable growth.

Key Numbers

• $2.44 million: Record September-quarter revenue, up 42% quarter-on-quarter.
• $831,569: Quarterly wholesale and business-to-business revenue, up approximately 172% from the preceding quarter.
• $25 million: Approximate minimum performance requirements under a three-year exclusive distribution agreement.
• $8.12 million: Record FY26 revenue, compared with $8.03 million in FY25.
• 33%: Reduction in annual operating cash outflows to $2.94 million.

Chairman outlines a stronger platform for global expansion

Chairman James Tonkin's address reinforces The Calmer Co's strategic transition towards higher-value botanical ingredients, international distribution and capital-efficient growth.

Rather than committing substantial capital to company-owned manufacturing facilities, the company is pursuing strategic partnerships and leveraging its established Pacific supply network.

Operations span Fiji, Papua New Guinea and Vanuatu, supporting a diversified supply of premium kava ingredients.

The company is also advancing water-extracted and supercritical CO₂ extraction capabilities to supply beverage manufacturers, nutraceutical businesses and wellness brands.

A binding heads of agreement with Kaiming Agro supports plans to establish commercial-scale extraction capabilities in Fiji.

This approach could improve production flexibility while positioning The Calmer Co to participate in the expanding market for functional beverages and natural wellness products.

A $25 million agreement opens a larger commercial opportunity

One of the company's most important developments is its exclusive distribution agreement with a multinational ingredients business.

Covering Australia, New Zealand, North America and ASEAN, the agreement includes approximately $25 million in minimum performance requirements over an initial three-year period to maintain exclusivity.

While these requirements do not represent guaranteed revenue, they establish a potentially substantial pathway for international wholesale expansion.

Commercial momentum is already strengthening.

September-quarter wholesale revenue reached $831,569, increasing approximately 172% from $305,740 in the preceding quarter.

Around 91% of wholesale revenue came from the United States, highlighting growing demand for the company's premium kava ingredients.

Kava extracts also increased their contribution to quarterly revenue from 16% to 26%.

This shift towards higher-value products could become an important driver of improved margins as production volumes increase.

Supermarket expansion strengthens the growth outlook

Australian retail operations are providing another encouraging source of momentum.

September-quarter retail revenue increased 25% to $975,037, supported by sales growth of 27% through Coles and 33% through Woolworths.

The company's products are now available across more than 3,400 retail distribution points.

Further expansion is expected through Fiji Kava FZZR, with Coles placing orders in October following the product's acceptance into its retail range.

The new format provides an opportunity to reach additional consumers while building on the established Fiji Kava brand.

Meanwhile, Amazon USA generated $461,003 during the September quarter, demonstrating the continuing importance of digital channels.

Together, retail, e-commerce and wholesale distribution are creating a more diversified revenue base.

Improving financial discipline supports the next growth phase

The Calmer Co's financial results also reveal progress towards a more efficient operating model.

FY26 revenue reached a record $8.12 million, while the annual net loss narrowed from $3.99 million to $3.81 million.

Operating cash outflows declined 33% from $4.37 million to $2.94 million, reflecting tighter expenditure controls.

However, gross margin decreased from 42.5% to 35.3%, highlighting the importance of improving product economics as sales expand.

The September quarter delivered further progress, with operating cash outflows of $755,000.

Cash reserves stood at $953,000 at 30 September 2026, making working capital management and additional funding important priorities.

Continued revenue expansion, disciplined expenditure and stronger margins could progressively improve the company's financial position.

Insight: Can premium kava ingredients accelerate the path to profitability?

What stands out to us is The Calmer Co's growing ability to combine established consumer brands with a potentially scalable international ingredients business. Wholesale revenue of approximately $832,000 in the September quarter provides encouraging evidence of commercial demand, while the $25 million distribution arrangement creates opportunities for further expansion. We see meaningful potential for stronger operating leverage as premium ingredient volumes increase. The next important test will be whether sustained wholesale growth translates into improved gross margins and lower operating cash outflows.

The verdict: Growing commercial momentum creates an encouraging outlook

The Calmer Co enters FY27 with record quarterly sales, expanding international distribution, stronger supermarket relationships and a more diversified business model.

Its capital-efficient strategy offers an attractive pathway to scale without requiring extensive investment in company-owned manufacturing infrastructure.

Although funding requirements and profitability remain important considerations, improving commercial momentum provides encouraging evidence that the company's strategy is gaining traction.

The next quarterly update will be particularly important for assessing wholesale order growth, Fiji Kava FZZR distribution, margin recovery and operating cash generation.

If management continues converting commercial opportunities into recurring revenue while maintaining cost discipline, The Calmer Co could establish a considerably stronger position in the global wellness and functional ingredients market.